FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Lupin Pharmaceuticals Quinapril Tablets Recall

Quinapril Tablets USP, 20 mg (90 pack), Rx Only, Manufactured for: Lupin Pharmaceutical…

Lupin Pharmaceuticals Inc. · Baltimore, MD

Risk level
Class II
Reported by FDA
Dec 28, 2022
Recall ID
D-0089-2023
Check your lot numberHow we source this data

Summary

Lupin Pharmaceuticals recalled Quinapril Tablets starting Dec 7, 2022. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0089-2023 on Dec 28, 2022. Reason: CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit. Status: Terminated.

Why it was recalled

CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Product description

Quinapril Tablets USP, 20 mg (90 pack), Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, by: Lupin Limited, Goa 403 722 India, NDC# 68180-558-09

Lot numbers, UPCs & expiration codes

Lot #: G102929, Exp 04/2023

Where it was sold

Product was distributed by major distribution chains nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0089-2023
Classification
Class II
Status
Terminated
Recall initiated
Dec 7, 2022
FDA report date
Dec 28, 2022
Quantity
23,736
Recall type
Voluntary: Firm initiated
Recalling firm
Lupin Pharmaceuticals Inc.

Original FDA data

Every field from FDA enforcement report D-0089-2023, exactly as published.

Show all FDA fields
City
Baltimore
State
MD
Status
Terminated
Country
United States
Event ID
91279
Address
Harborplace Tower
Address (line 2)
111 S Calvert St Fl 21st
Code information
Lot #: G102929, Exp 04/2023
Postal code
21202-6174
Report date
Dec 28, 2022
Product type
Drugs
Recall number
D-0089-2023
Classification
Class II
Recalling firm
Lupin Pharmaceuticals Inc.
Product quantity
23,736
Termination date
Aug 1, 2024
Reason for recall
CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Quinapril Tablets USP, 20 mg (90 pack), Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, by: Lupin Limited, Goa 403 722 India, NDC# 68180-558-09
Distribution pattern
Product was distributed by major distribution chains nationwide.
Recall initiation date
Dec 7, 2022
Initial firm notification
Letter
Center classification date
Dec 23, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0089-2023, published Dec 28, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls